Deucravacitinib (2) – Sotyktu®
Psoriatic arthritis, as monotherapy or in combination with methotrexate
Characteristics
| Start date | 01.06.2026 |
|---|---|
| Resolution | 19.11.2026 – active procedure |
| INN | Deucravacitinib |
| Brand name | Sotyktu® |
| Pharm. company | Bristol-Myers Squibb GmbH & Co. KGaA |
| G-BA Procedure ID | D-1348 |
| Therapeutic area | Skin diseases |
| Reason for procedure | New therapeutic indication |
Associated procedures
<< List of all resolutions